{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977427",
  "id": "02977427",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0938",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml86xg3cbxlk.pdf",
  "summary": "**Clinical Trial Update Announcement**  \n\n- **Phase I Trial Results:**  \n  - No dose-limiting safety signals observed; Xolatryp\u2122 well tolerated in all 48 participants (40 drug, 8 placebo).  \n  - Unblinding and topline results expected in **September 2025 quarter**.  \n  - Database lock anticipated by **end-August 2025**.  \n\n- **Phase IIa Trial Plan:**  \n  - Targeting **early 2026** for Phase IIa in acute myocardial infarction (STEMI patients).  \n  - Ethics submission for Phase IIa expected post Clinical Study Report finalization (**November 2025**).  \n\n**Key Implications:**  \n- Positive safety data supports progression to Phase IIa, derisking near-term clinical development.  \n- Upcoming catalysts: September 2025 topline results and Phase IIa trial initiation timeline.  \n\n*No material capital markets or liquidity impacts identified.*",
  "usage": {
    "prompt_tokens": 2057,
    "completion_tokens": 192,
    "total_tokens": 2249,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-06T00:11:24.214157"
}